Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190456 | 1.00 | ADRA1D (0.52) | ADRA1DADRA1AADRA1BACE2SMN1; SMN2 | |
| SCHEMBL1188968 | 1.00 | ADRA1D (0.52) | ADRA1DADRA1AADRA1BACE2SMN1; SMN2 | |
| SCHEMBL1189314 | 0.81 | HTR2C (0.52) | ACE2SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1189578 | 0.81 | HTR2C (0.52) | ACE2SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1189692 | 0.81 | HTR2C (0.52) | ACE2SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1190558 | 0.81 | HTR2C (0.52) | ACE2SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1189693 | 0.81 | HTR2C (0.52) | ACE2SMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL30315793 | 0.81 | PDK1 (0.51) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL30315726 | 0.81 | PDK1 (0.51) | SMN1; SMN2NPC1RAB9APREPCYP2C19 | |
| SCHEMBL18477527 | 0.79 | FKBP1A (0.52) | PREPSIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217226-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2217226-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009061879-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | ADRA1D 4250/4885ADRA1A 4520/4885ADRA1B 4251/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | ADRA1D 3358/4885ADRA1A 3940/4885ADRA1B 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.